Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · MANGOCEUTICALS, INC. (MGRX)

Mangoceuticals terminates Nuclea Energy business combination agreement

Negative Impact 4 of 5 m&a Written later

Mangoceuticals and Nuclea Energy mutually agreed on August 19, 2026 to terminate their Business Combination Agreement, which had been dated July 29, 2026. The parties said the $15,000,000 PIPE financing minimum could not be raised by the August 21, 2026 outside date, so the financing closing condition could not be met on the agreed terms.

Key points

  • Termination agreed August 19, 2026 under Section 12.1(a) of the agreement, which was dated July 29, 2026
  • Closing required PIPE financing of at least $15,000,000 deposited into escrow; the outside date was August 21, 2026
  • Each party bears its own costs, and the parties exchanged mutual releases except for willful breaches before termination

The filing

CompanyMANGOCEUTICALS, INC. (MGRX)
Form8-K, current report
Filed with the SECAug 21, 2026, 5:15 PM ET
Accession number0001493152-26-039724

Items reported: 1.02 Termination of Material Agreement

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 21, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.